Project Grant K08HL177281
- The Children's Hospital of Philadelphia (CHOP) has been awarded a $1,029,350 project grant by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to conduct a study titled "Cardiometabolic Risk and Comorbidities in Adults with Down Syndrome - Electronic Health Record Examination (CASCADE)". The study aims to: Describe the prevalence of type 2 diabetes, dyslipidemia, hypertension, and obstructive sleep apnea, as well as quantify HbA1c and lipid...
- This $462,454 Project Grant award, provided by the Department of Health and Human Services National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310), aims to characterize DNA methylation dynamics in trisomy 21-associated hematopoiesis and leukemia. The project, awarded to the Icahn School of Medicine at Mount Sinai, will employ the institution's innovative single-cell multi-omic sequencing technology, SHARE-ME-SEQ, to map DNA methylation, chromatin...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research on the role of extracellular matrix (ECM) in the development of congenital heart defects associated with Down syndrome (DS). The $233,088 award will fund the development of 3D cardiac models to investigate how disruptions in ECM and cell-ECM interactions during heart development lead to downstream effects on cell signaling, cytoskeletal reorganization,...
- This $445,000 Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research at The Children's Hospital of Philadelphia (CHOP) to investigate how the tropomyosin 1 gene product impacts the development of hematopoietic stem and progenitor cells and their precursors. The goal is to define genetic determinants of hematopoiesis that could enhance in vitro production of blood cells to support research and development of blood...
- This federal Project Grant award of $445,000.00 was provided by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837) to The Children's Hospital of Philadelphia (CHOP) Research Institute. The goal of this 3-year project is to define the mechanisms by which impaired mitochondrial function leads to the failure of neutrophil development and how neutrophil precursors use somatic mutations to adapt to this cell-intrinsic stress in severe...
- This federal Project Grant award for $152,816.00, provided by the National Institute of Child Health and Human Development (CFDA 93.865 - Child Health and Human Development Extramural Research), aims to investigate the link between Down's syndrome (trisomy 21) and placentation defects. The research will focus on: Identifying transcriptional differences in implantation-stage trophoblasts between trisomy 21 and euploid induced pluripotent stem cell lines through RNA-sequencing. Assessing the...
- The Children's Hospital of Philadelphia (CHOP) received a $732,541 Project Grant award from the National Institutes of Health (NIH) Trans-NIH Research Support program (CFDA 93.310). The goal of this 24-month grant, awarded on August 7, 2025, is to develop a transdisciplinary training program to foster a new generation of investigators to pursue research in youth and adults with Down syndrome (DS). The PARTNERS program will provide a week-long in-person short course at CHOP, supplemented by...
- This Project Grant award for $879,567.00, funded by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), supports research on lung injury in pediatric hematopoietic cell transplant (HCT) recipients. The research team at The Children's Hospital of Philadelphia (CHOP) will conduct a comprehensive characterization of the clinical, proteomic, and cell-free DNA biomarker profiles associated with the development of lung injury after HCT in...
- This Project Grant awarded by the National Institute of Child Health and Human Development (NICHD), under the Child Health and Human Development Extramural Research Federal Grant Program (CFDA 93.865), provides $147,486 to The Johns Hopkins University to investigate the impact of chromosome 21 dosage on placental function and neurodevelopment in Down Syndrome. The research aims to determine how increased dosage of genes on chromosome 21, such as APP and SOD1, affects placental secretome and...
- The Project Grant award of $451,000.00 from the National Institutes of Health (NIH) Trans-NIH Research Support program (CFDA 93.310) is funding research at the University of Texas Southwestern Medical Center (UT Southwestern) to identify genes on human chromosome 21 that contribute to the neurological and developmental impairments associated with Down syndrome. The 2-year project will use CRISPR interference (CRISPRi) technology and induced pluripotent stem cells (iPSCs) derived from individuals...
This $158,976 Project Grant was awarded by the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to The Children's Hospital of Philadelphia (CHOP) to investigate the mechanisms underlying hematopoietic disorders associated with Down syndrome (trisomy 21). The research aims to use a novel human induced pluripotent stem cell system to isolate the individual and synergistic roles of trisomy 21, the GATA1S transcription factor mutation, RUNX1 isoforms, and STAG2 loss in the development of transient abnormal myelopoiesis and myeloid leukemia of Down syndrome. The findings could lead to improved understanding and potential treatment approaches for these complex hematopoietic disorders unique to individuals with Down syndrome.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $159.0k | 8/13/25 |